IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Allchem Lifescience IPO is a Book Building listing on BSE,NSE exchange. The company is based in Vadodara and caters to Pharmaceutical sector. Emkay Global Financial Services is the merchant banker of Allchem Lifescience IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 13th March 2025.
Allchem Lifescience IPO posted revenues of ₹ 156.90 crores and PAT of ₹ 21.78 crores in FY25 on annualised basis.
Revenue:
₹ 156.80 Cr.
EBITDA Margin:
40.94
% 
Net Worth: ₹ 90.70 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Allchem Lifescience IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Sep-24 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 246.30 | 224.65 | 186.60 | 124.02 | |
| Net Worth | 90.70 | 79.80 | 56.40 | 38.50 | |
| Total Debt | 106.80 | 104.90 | 87.10 | 49.40 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
78.40
156.80 |
137.40 | 105.70 | 108.10 | |
EBITDA
EBITDA on annualised basis |
32.10
64.20 |
52.20 | 30.40 | 24.90 | |
PAT
PAT on annualised basis |
10.80
21.60 |
23.40 | 17.90 | 14.10 | |
Allchem Lifescience IPO PAT Margin is 13.78 % , ROCE (Return on Capital Employed) is 10.90 % as per latest financial. The below table shows Allchem Lifescience IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Sep-24 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| EBITDA Margin (%) | 40.94 | 37.99 | 28.76 | 23.03 |
| PAT Margin (%) | 13.78 | 17.03 | 16.93 | 13.04 |
| EPS (₹) | 1.42 | 3.06 | 2.36 | 2.24 |
| ROE (%) | 11.91 | 29.32 | 31.74 | 36.62 |
| ROCE (%) | 10.90 | 22.87 | 23.49 | 35.76 |
| ROA (%) | 4.38 | 10.42 | 9.59 | 11.37 |
| Debt to Equity | 1.18 | 1.31 | 1.54 | 1.28 |
The market Capitalisation of Allchem Lifescience IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
Revenue:
₹ 156.80 Cr.
EBITDA Margin:
40.94
%
Net Worth: ₹ 90.70 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
The Allchem Lifescience IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Allchem Lifescience IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Allchem Lifescience IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Allchem Lifescience IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Allchem Lifescience IPO reported revenue of ₹ 156.90 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Allchem Lifescience IPO provide insights into sales growth, market demand, and business scalability.
Allchem Lifescience recorded an EBITDA of ₹ 64.20 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Allchem Lifescience Profit After Tax (PAT) is ₹ 21.60 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Allchem Lifescience operates in Pharmaceutical and Manufacturer Of Active Pharmaceutical Ingredients (API) Intermediates. The Issue is listed on BSE,NSE in May, 2025. Allchem Lifescience IPO size was with Issue price of .
Merchant Banker(s) of Allchem Lifescience IPO: Emkay Global Financial Services Limited
Allchem Lifescience IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Allchem Lifescience IPO listed at a listing price of against the offer price of .
The current market price of Allchem Lifescience is .
Why Us?
